IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.
About IPO Scanner
IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.
Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.
Details of client bank account
For any query / feedback / clarifications, email at
[email protected].
Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.
© 2026 IPO Scanner. All rights reserved.
Want to stay updated?Subscribe to our newsletter

USD · NASDAQ:AVLN
Issue Size
$300.00M
Price Range
$16.00 - $18.00
Shares
41.81M o/s · 16.67M offered
Listing Price
$26.00
Avalyn Pharma Inc.
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs.
Its current pipeline is focused on treating pulmonary fibrosis.
Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms.
Ticker, listing venue and issuer profile
Pricing terms and IPO milestones
Change from offer price to today
Real-time price; headline % change is vs first trade (listing price)
USD · NASDAQ:NASDAQ:AVLN
Key valuation ratios and metrics
Balance sheet strength and liquidity
Margins and return on capital
Historical financial performance
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-05-14 | $30.77 | $31.34 | $28.80 | $30.62 | $30.62 | -0.15 | 178,200 |
| 2026-05-13 | $29.92 | $32.23 | $28.36 | $30.83 | $30.83 | +0.91 | 402,300 |
| 2026-05-12 | $29.27 | $31.02 | $29.25 | $29.90 | $29.90 | +0.63 | 308,600 |
| 2026-05-11 | $27.28 | $30.43 | $27.27 | $29.57 | $29.57 | +2.29 | 306,700 |
| 2026-05-08 | $26.66 | $29.00 | $26.64 | $27.33 | $27.33 | +0.67 | 290,400 |
| 2026-05-07 | $27.43 | $27.50 | $25.39 | $26.93 | $26.93 | -0.50 | 664,400 |
| 2026-05-06 | $27.16 | $27.74 | $25.05 | $27.71 | $27.71 | +0.55 | 673,800 |
| 2026-05-05 | $29.32 | $29.64 | $25.44 | $27.43 | $27.43 | -1.89 | 468,000 |
| 2026-05-04 | $30.14 | $30.67 | $28.01 | $29.07 | $29.07 | -1.07 | 357,300 |
| 2026-05-01 | $28.00 | $30.00 | $27.50 | $29.84 | $29.84 | +1.84 | 830,000 |
| 2026-04-30 | $26.00 | $30.20 | $26.00 | $29.49 | $29.49 | +3.49 | 6,512,000 |
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| SCHEDULE 13D | May 8, 2026 | Filing |
| SCHEDULE 13D | May 8, 2026 | Filing |
| SCHEDULE 13G | May 7, 2026 | Filing |
| SCHEDULE 13G | May 5, 2026 | Filing |
| 8-K | May 1, 2026 | Current Report |
| S-8 | Apr 30, 2026 | Securities to be offered to employees in employee benefit plans |
| 424B4 | Apr 30, 2026 | Prospectus |
| EFFECT | Apr 29, 2026 | Notice of Effectiveness |
| CERT | Apr 29, 2026 | Certification by an exchange approving securities for listing |
| S-1/A | Apr 29, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
Contact and headquarters details
Key executives and officers
Lyn Baranowski
Chief Executive Officer and Director
Douglas Carlson
Chief Financial Officer and Chief Business Officer
Melissa Rhodes, Ph.D., D.A.B.T
Chief Operating Officer
Howard M. Lazarus, M.D., FCCP
Chief Medical Officer
Heather Turner
Director and Board Chair
Tiba Aynechi, Ph.D.
Director
Jill Carroll
Director
Jon Congleton
Director
David Friedman, M.D.
Director
Kate Haviland
Director
Listing date
Apr 30, 2026
Sector
Healthcare